Prostate Cancer Market By Type (Medication (Hormone Therapy, Chemotherapy, Immunotherapy), Radiation Therapy (External-beam Radiation Therapy, and Brachytherapy), Focal Therapy (Cryosurgery, High-intensity Focused Ultrasound (HIFU))), By End User (Hospitals, Ambulatory Surgical Centre's, and Others), Industry Trends, Estimation & Forecast, 2023-2030

Market Overview

Prostate cancer happens in the prostate gland, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. The prostate cancer types include adenocarcinomas, Small cell carcinomas, Neuroendocrine tumors, Transitional cell carcinomas, and Sarcomas. Treatment for prostate cancer includes Surgery, Radiation therapy, Focal therapies, Testosterone suppression therapy and androgen axis inhibitors, Chemotherapy, and Immunotherapy.

Prostate Cancer market was valued at 11 billion US$ in 2022 and is projected to reach 21.1 billion US$ by 2030, at a CAGR of 8.5% during the forecast period.

Market Dynamics

Rising prevalence of prostate cancer is one of the key factor boosting the global prostate cancer market. For instance, according to the American Cancer Society, it is estimated that in 2020 there will be 191,930 new cases of prostate cancer and 33,330 deaths from prostate cancer in the United States. According to the Cancer Research UK, there are over 48,500 new prostate cancer cases in the UK every year. Prostate cancer accounts for 26% of all new cancer cases in males in the UK. According to the Australian Institute of Health and Welfare, in 2019, there were 19,508 new cases of prostate cancer and 3,306 deaths from prostate cancer in Australia. According to the Pan-American Health Organisation, the incidence rate of prostate cancer and deaths from this disease are expected to double in Brazil by 2030. Further, advancement in oncology screening and diagnostics are key driving factors of the market. However, High cost of prostate cancer diagnostic tests might hamper the market growth. For example, in Brazil, the economic cost of prostate cancer may rise by 50% to USD 1.8bn per year by 2022. Moreover, increasing Government Initiatives and funding would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global Prostate Cancer market is mainly classified based on Type, End User. Type is further segmented into Medication (Hormone therapy, Chemotherapy, Immunotherapy), Radiation Therapy (External-beam radiation therapy, Brachytherapy), Focal Therapy (Cryosurgery, High-intensity focused ultrasound (HIFU)). By End User, the market is divided into Hospitals, Ambulatory Surgical Centre’s, Others.

Medication segment was dominating the global prostate cancer market in 2019. The regulatory approval for manufacturing and commercializing prostate cancer medication is boosting the global prostate cancer market. For instance, Pfizer Inc. and Astellas Pharma Inc. have received the U.S. Food and Drug Administration (FDA) approval for supplemental New Drug Application (sNDA) for XTANDI (enzalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). Enzalutamide is a hormon treatment which blocks testosterone from reaching prostate cancer cells. Moreover, The U.S. Food and Drug Administration has approved Erleada (apalutamide) and Nubeqa (darolutamide) for the treatment of patients with prostate cancer. Erleada is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer. Nubeqa is an androgen receptor inhibitor (ARi) to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Regional Analysis

Based on geography, the global Prostate Cancer market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global prostate cancer market in 2019. The increasing prevalence of prostate cancer, the partnership between companies to develop products, commercialization of new product, regulatory approval for prostate cancer products and government initiative and funding for prostate cancer research, are some of the factors boosting the North America prostate cancer market. For instance, NIH and Prostate Cancer Foundation have introduced a study on aggressive prostate cancer in African American men. It is a $26.5 million study called RESPOND. This study will identify environmental and genetic factors related to the aggressiveness of prostate cancer in African American men.

Competitive landscape

Key players operating in the Prostate Cancer industry include Johnson & Johnson, Astella, Inc., Sanofi Aventis, IPSEN, Bayer AG, AstraZeneca, Ipsen SA, Abbvie Inc., Dendreon Pharmaceuticals LLC, Tolmar Inc.

The commercialization of new product, regulatory approval for prostate cancer products, government funding for prostate cancer research, and partnership between companies to conduct studies on prostate cancer, are some of the strategies adopted by the companies. For instance, on October 25, 2019, Anixa Biosciences, Inc., a biotechnology company, has collaborated with Urology San Antonio, PA, in Anixa’s ongoing Cchek prostate cancer study. The collaboration would improve patient care. Cchek is a cancer detection technology, which measures the patient’s immunological response to malignancy by analyzing immune system cells in peripheral blood.

Prostate Cancer Market Key Segments

By Type
• Medication
o Hormone therapy
o Chemotherapy
o Immunotherapy
• Radiation Therapy
o External-beam radiation therapy
o Brachytherapy
• Focal Therapy
o Cryosurgery
o High-intensity focused ultrasound (HIFU)

By End-User
• Hospitals
• Ambulatory Surgical Centre’s
• Others

Key Global Prostate Cancer Industry Players

• Johnson & Johnson
• Astella, Inc.
• Sanofi Aventis
• IPSEN
• Bayer AG
• Astrazeneca
• Ipsen SA
• Abbvie Inc.
• Dendreon Pharmaceuticals LLC
• Tolmar Inc.

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Prostate Cancer Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Rising prevalence of prostate cancer
3.3.2. Advancement in oncology screening and diagnostics
3.4. Restraints
3.4.1. High cost of prostate cancer diagnostic tests
3.5. Opportunity
3.5.1. Increasing Government Initiatives and funding
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Medication
4.2.1. Market Size & Forecast
4.2.1.1. Hormone therapy
4.2.1.2. Chemotherapy
4.2.1.3. Immunotherapy
4.3. Radiation Therapy
4.3.1. Market Size & Forecast
4.3.1.1. External-beam radiation therapy
4.3.1.2. Brachytherapy
4.4. Focal Therapy
4.4.1. Market Size & Forecast
4.4.1.1. Cryosurgery
4.4.1.2. High-intensity focused ultrasound (HIFU)

5. End-User Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Hospitals
5.2.1. Market Size & Forecast
5.3. Ambulatory Surgical Centre’s
5.3.1. Market Size & Forecast
5.4. Others
5.4.1. Market Size & Forecast

6. Prostate Cancer Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Prostate Cancer Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By End User
6.2.4. The U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Prostate Cancer Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By End User
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Prostate Cancer Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By End User
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Prostate Cancer Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By End User
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Prostate Cancer Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By End User
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Johnson & Johnson
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Johnson & Johnson Product Category, Application, and Specification
7.1.3. Johnson & Johnson Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Astella, Inc.
7.3. Sanofi Aventis
7.4. IPSEN
7.5. Bayer AG
7.6. Astrazeneca
7.7. Ipsen SA
7.8. Abbvie Inc.
7.9. Dendreon Pharmaceuticals LLC
7.10. Tolmar Inc.